Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (710)	6/28/2001 9:42:21 AM
From: tuck	Read Replies (1) \| Respond to of 1784

Crossy, I think Nigel suggested OXIG way back when, but I believe their revenue is less than 50% from life sciences, which is my usual criterion for qualification as a "trickle" company. PKI flunked that test for similar reasons. VARI, which uses those magnets in its NMR spectrometers, qualified for a little while. Anyhow, I was plugging QGENF as a consumables company (last CC they said instrument sales accounted for 12% of revenue), and here they go and make a pharma sale. Let's hope it helps now that I've doubled down. This marks the first sale arising from the ZeptoSens collaboration, so good news. >>VENLO, Netherlands, June 28 /PRNewswire/ -- QIAGEN N.V. (Nasdaq: QGENF - news; Neuer Markt: QIA; Easdaq: QGEN) today announced that it has entered into a technology access and evaluation agreement with Aventis Pharma, the pharmaceutical company of Aventis (NYSE: AVE; Frankfurt: AVEP; Paris: AVEP). Under the terms of this agreement Aventis will gain limited access to the ZeptoGene Workstation technology platform. Financial terms were not disclosed. The ZeptoGene Workstation, the first product available from QIAGEN which was developed in alliance with Zeptosens AG, is based on Planar Waveguide (PWG) Technology. The cutting-edge PWG Array Technology allows the use of minimal sample amounts for the analysis of the differential expression pattern of genes that are expressed at very low levels. Its extremely high sensitivity allows users to avoid cumbersome, expensive and information- distorting amplification procedures such as PCR. Aventis Pharma and QIAGEN believe that the ZeptoGene Workstation demonstrates the power of Zeptosens' proprietary PWG Chip technology and that it has the potential to set a new standard in sensitivity and speed in microarray analysis. Dr. Ulrich Schriek, Vice President of Corporate Business Development at QIAGEN remarked: ``Our exclusive access to Zeptosens' PWG technology for nucleic acids and certain protein areas allows QIAGEN to create a very strong position in an exciting niche of the microarray market. The technology's ultra high sensitivity and reproducibility, as well as its applicability to both nucleic acids and proteins make it a very unique product for: -- in depth, secondary analysis of data derived on conventional arrays; -- the detection of expression patterns not detectable on conventional arrays due to extremely low signals or distortion in the amplification processes required by conventional technologies; and -- the analysis of interrelations between genomic and proteomic samples on one platform. The Zeptosens products are combined with QIAGEN's leading nucleic acid separation, purification and handling technologies to form a complete, integrated analysis line. We are very pleased to add Aventis to the users of our PWG technology.`` Dr. Jutta Reinhard-Rupp, Head of Functional Genomics, Frankfurt, of Aventis Pharma in Germany stated: ``The PWG Chip technology has the potential to give us more precise information about the expression pattern of genes that are expressed at very low levels and only slightly differentially expressed genes. This advantage can significantly accelerate our target validation process and will support our understanding of diseases and their mechanisms. We are excited to be one of the first access partners for this exciting technology platform.''<< snip Would NABI make the ">50% from life sciences revenue"" cut, Crossy? Cheers, Tuck